Retinoic acid receptor alpha, Retinoic acid receptor beta (RAR-α, RAR-β)

Retinoic acid receptor alpha and retinoic acid receptor beta are nuclear receptors that function as ligand-activated transcription factors, binding retinoic acid (a vitamin A derivative) and regulating gene transcription crucial for cell differentiation, growth, and embryonic development[1][4][6]. They act as heterodimers (typically with retinoid X receptors), with ligand binding causing a conformational change resulting in the displacement of corepressors and recruitment of coactivators, ultimately activating the transcription of downstream genes[1][3][6]. RAR-α, encoded by the RARA gene, and RAR-β, encoded by the RARB gene, have overlapping and subtype-specific roles in development, homeostasis, and disease. Their dysfunction or altered expression is implicated in various pathologies, most notably in acute promyelocytic leukemia, where RARA gene rearrangements create oncogenic fusion proteins. Pharmacological targeting, especially with retinoids, has validated both as therapeutic targets, with drugs like all-trans retinoic acid achieving high efficacy in acute promyelocytic leukemia[1][4]. Both receptors are subject to complex regulation, including alternative splicing, heterodimerization with RXRs, and modulation by cellular signaling pathways.

Other names

NR1B1 (for RAR-α)NR1B2 (for RAR-β)RARA (gene for alpha)RARB (gene for beta)nuclear receptor subfamily 1 group B member 1/2

Ligand binding (e.g., retinoic acid) induces conformational change, triggers dissociation of corepressors and recruitment of coactivators, leading to target gene activation; Antagonists block ligand-induced activity